Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) major shareholder Venrock Healthcare Capital Par bought 8,971 shares of Oruka Therapeutics stock in a transaction dated Wednesday, February 12th. The stock was purchased at an average cost of $11.86 per share, for a total transaction of $106,396.06. Following the completion of the acquisition, the insider now directly owns 4,044,684 shares of the company's stock, valued at approximately $47,969,952.24. The trade was a 0.22 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Major shareholders that own at least 10% of a company's stock are required to disclose their sales and purchases with the SEC.
Venrock Healthcare Capital Par also recently made the following trade(s):
- On Friday, February 14th, Venrock Healthcare Capital Par acquired 88,794 shares of Oruka Therapeutics stock. The shares were acquired at an average price of $11.44 per share, with a total value of $1,015,803.36.
- On Monday, February 10th, Venrock Healthcare Capital Par purchased 574 shares of Oruka Therapeutics stock. The stock was acquired at an average cost of $10.90 per share, with a total value of $6,256.60.
Oruka Therapeutics Stock Down 9.2 %
Shares of NASDAQ ORKA opened at $9.56 on Friday. The company has a 50 day moving average price of $14.49. The stock has a market capitalization of $334.59 million, a price-to-earnings ratio of -1.53 and a beta of 0.77. Oruka Therapeutics, Inc. has a 52-week low of $9.53 and a 52-week high of $53.88.
Analyst Ratings Changes
Several equities research analysts have recently issued reports on ORKA shares. Wolfe Research initiated coverage on shares of Oruka Therapeutics in a report on Tuesday, February 4th. They issued an "outperform" rating and a $20.00 target price for the company. HC Wainwright reissued a "buy" rating and issued a $45.00 price objective on shares of Oruka Therapeutics in a research note on Friday, February 7th. Finally, Wedbush reaffirmed an "outperform" rating and set a $40.00 target price on shares of Oruka Therapeutics in a research note on Tuesday, November 19th. Seven investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Oruka Therapeutics presently has an average rating of "Buy" and an average target price of $39.86.
Read Our Latest Analysis on ORKA
Institutional Investors Weigh In On Oruka Therapeutics
Several hedge funds have recently made changes to their positions in ORKA. JPMorgan Chase & Co. bought a new position in shares of Oruka Therapeutics during the fourth quarter valued at approximately $54,000. AlphaCentric Advisors LLC purchased a new position in Oruka Therapeutics in the fourth quarter valued at about $119,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Oruka Therapeutics during the 4th quarter worth approximately $144,000. Squarepoint Ops LLC purchased a new stake in shares of Oruka Therapeutics during the 4th quarter valued at $236,000. Finally, Charles Schwab Investment Management Inc. acquired a new position in Oruka Therapeutics during the 4th quarter valued at about $303,000. 56.44% of the stock is currently owned by hedge funds and other institutional investors.
Oruka Therapeutics Company Profile
(
Get Free Report)
Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
